[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f65-g5LTUgHIk8dGZIHhGe2pKpxnfW0g-O4HGxk3yxcs":3,"$fak5_Q0R06NoYcXRSaxxeI2FrsbZIw3-GOJP_aRF7MOY":8,"$fgBMo3onmnm4sbCYobstyzx9HGvU7jCBfQWZOklbq0rs":55,"$fIxNuY3TpZoj4wDSRSBCLtfzXoBMZINTsVtk9aApjwr0":59},{"code":4,"msg":5,"message":6,"data":6,"success":7},401,"认证失败，无法访问系统资源",null,false,{"code":9,"msg":10,"message":6,"data":11,"success":54},200,"操作成功",{"id":12,"specialistId":13,"specialistAssistants":14,"profilePhoto":15,"specialistName":16,"hospital":17,"department":18,"postsTitle":19,"materialTotal":20,"videoTotal":21,"isConcern":7,"title":22,"coverVertical":23,"coverAcross":24,"content":25,"description":26,"views":27,"likes":21,"isThumbsUp":7,"isCollection":7,"collections":21,"createTime":28,"seoTitle":22,"seoKeywords":29,"seoDescription":30,"shelvesTime":31,"version":32,"menus":33,"menuId":35,"type":42,"quality":53,"commentCount":21,"isComment":42},58919,867323,[],"https://ystcdn.venuertc.com/learnMaterial/ystApp//VjxO4NeO7R7u8VxE20BMmMakCRoDYTJ8.png","徐家亮","瓦房店市中心医院","肿瘤科","主任医师",99,0,"TCbHP化疗方案用药要点全解——曲妥珠单抗、帕妥珠单抗、多西他赛、卡铂安全用药指南","","https://ystcdn.venuertc.com/venue/AI/3c7eeca9-734e-4ebd-a958-a3dacc55b967.jpg","\u003Cdiv class=\"material-guide-container\">\n  \u003Ch2 id=\"material_title\" class=\"material-title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">TCbHP化疗方案用药要点全解\u003Cbr>——曲妥珠单抗、帕妥珠单抗、多西他赛、卡铂安全用药指南\u003C/h2>\n  \u003Cdiv class=\"material-lead\">\n    \u003Cspan class=\"material-emoji\">💊\u003C/span>\n    \u003Cspan class=\"material-lead-text\">\n      在日常肿瘤治疗中，TCbHP化疗方案所用的四种药物——曲妥珠单抗、帕妥珠单抗、多西他赛和卡铂，有着各自独特的药理特性和使用要求。想要安全、高效地用药，需要掌握一系列关键的使用细节。今天，我们来聊聊这4种药品，每种的核心用药要点、剂型储存、常见风险应对和注意事项，帮你一文掌握，安心用药不走弯路。\n    \u003C/span>\n  \u003C/div>\n\n  \u003Csection class=\"material-section\">\n    \u003Ch2 class=\"material-section-title material-bg1\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">1. 药品基础知识与机制\u003Cbr>——4种药品的核心特点\u003C/h2>\n    \u003Cul class=\"material-list\">\n      \u003Cli>\n        \u003Cb>曲妥珠单抗（Trastuzumab）：\u003C/b> 重组人源化单克隆抗体，通过特异性结合HER2受体，阻断相关信号传导，提高细胞凋亡（参考：Slamon DJ et al., 2001, N Engl J Med）。\n      \u003C/li>\n      \u003Cli>\n        \u003Cb>帕妥珠单抗（Pertuzumab）：\u003C/b> 单克隆抗体，靶向HER2与HER3的结合部位，联合曲妥珠单抗可增强阻断肿瘤信号通路（Baselga J et al., 2012, N Engl J Med）。\n      \u003C/li>\n      \u003Cli>\n        \u003Cb>多西他赛（Docetaxel）：\u003C/b> 紫杉类化疗药，抑制微管解聚，使癌细胞无法分裂，诱发细胞死亡（Fumoleau P et al., 1995, J Clin Oncol）。\n      \u003C/li>\n      \u003Cli>\n        \u003Cb>卡铂（Carboplatin）：\u003C/b> 铂类化疗药，通过DNA交联作用破坏癌细胞DNA，阻断其复制（Calvert AH et al., 1989, J Clin Oncol）。\n      \u003C/li>\n    \u003C/ul>\n    \u003Cdiv class=\"material-tip\">\u003Cspan class=\"material-emoji\">🔬\u003C/span>药理机制只需了解其“封锁、破坏或杀伤”肿瘤细胞的基本作用，提高了联合治疗的效果。\u003C/div>\n  \u003C/section>\n\n  \u003Csection class=\"material-section\">\n    \u003Ch2 class=\"material-section-title material-bg2\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">2. 剂型特性与使用技巧\u003Cbr>——从配置到输注的重点\u003C/h2>\n    \u003Cul class=\"material-list\">\n      \u003Cli>\n        \u003Cb>曲妥珠单抗：\u003C/b>粉剂瓶或现成注射液，仅供静脉注射。配制后立即使用，最长存放不宜超过24小时，推荐于2°C-8°C冷藏。\n      \u003C/li>\n      \u003Cli>\n        \u003Cb>帕妥珠单抗：\u003C/b>注射用浓溶液，需于2°C-8°C保存，用前稀释，确保配液溶解后均匀无沉淀。\n      \u003C/li>\n      \u003Cli>\n        \u003Cb>多西他赛：\u003C/b>注射液，需稀释后静脉点滴，操作时应带专用手套，防止药液皮肤接触。\n      \u003C/li>\n      \u003Cli>\n        \u003Cb>卡铂：\u003C/b>注射用粉剂或注射液，静脉点滴，配制好后应尽快使用，如需存储保持2°C-8°C。\n      \u003C/li>\n    \u003C/ul>\n    \u003Cdiv class=\"material-tip\">\u003Cspan class=\"material-emoji\">⚗️\u003C/span>正确做法：药物需由专业人员配置和给药，家庭不宜自行操作。\u003C/div>\n  \u003C/section>\n\n  \u003Csection class=\"material-section\">\n    \u003Ch2 class=\"material-section-title material-bg3\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">3. 合理用法与用量把握\u003Cbr>——每种药品的标准流程\u003C/h2>\n    \u003Cul class=\"material-list\">\n      \u003Cli>\n        \u003Cb>曲妥珠单抗：\u003C/b>首次用药先给予负荷剂量，后续按体重给定维持剂量。输注速度初次较慢，监测过敏反应，无不适时再逐步加快。\n      \u003C/li>\n      \u003Cli>\n        \u003Cb>帕妥珠单抗：\u003C/b>第一剂同样需负荷剂量，后依体重调整，和曲妥珠单抗协同使用，全程静脉输注。\n      \u003C/li>\n      \u003Cli>\n        \u003Cb>多西他赛：\u003C/b>按体表面积计算剂量，常规3周一次，严格根据药师指导调整。\n      \u003C/li>\n      \u003Cli>\n        \u003Cb>卡铂：\u003C/b>剂量依据肾功能、体表面积和AUC值（受区下面积）评定，避免过量。\n      \u003C/li>\n    \u003C/ul>\n    \u003Cdiv class=\"material-tip\">\u003Cspan class=\"material-emoji\">⌛\u003C/span>用药间期、持续时间按方案执行，擅自提前或延后均有风险。 \u003C/div>\n  \u003C/section>\n\n  \u003Csection class=\"material-section\">\n    \u003Ch2 class=\"material-section-title material-bg4\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">4. 药品相互作用和联合用药风险\u003C/h2>\n    \u003Cul class=\"material-list\">\n      \u003Cli>\n        \u003Cb>曲妥珠单抗、帕妥珠单抗：\u003C/b>和蒽环类药物合用时，心脏毒性风险显著增加。与其它HER2靶向药物同时使用必须遵循专业方案。\n      \u003C/li>\n      \u003Cli>\n        \u003Cb>多西他赛：\u003C/b>避免与CYP3A4抑制剂（如酮康唑、红霉素）合用，否则可加重多西他赛毒性。\n      \u003C/li>\n      \u003Cli>\n        \u003Cb>卡铂：\u003C/b>避免合用其他肾毒性药物（如庆大霉素），防止肾损伤叠加。\n      \u003C/li>\n      \u003Cli>\n        \u003Cb>四药联合：\u003C/b>应权衡交互影响，密切监测骨髓抑制、肝肾损伤等风险。\n      \u003C/li>\n    \u003C/ul>\n    \u003Cdiv class=\"material-tip\">\u003Cspan class=\"material-emoji\">🧬\u003C/span>正确做法：每次就诊告知医生近期所有用药，避免出现不明相互作用。\u003C/div>\n  \u003C/section>\n\n  \u003Csection class=\"material-section\">\n    \u003Ch2 class=\"material-section-title material-bg1\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">5. 不良反应识别与处理方法\u003C/h2>\n    \u003Cul class=\"material-list\">\n      \u003Cli>\n        \u003Cb>骨髓抑制：\u003C/b>四药可导致血细胞下降，表现为白细胞、红细胞或血小板减少。出现IV度骨髓抑制时，需暂停下一周期化疗，必要时予粒细胞刺激因子或输血支持。\n      \u003C/li>\n      \u003Cli>\n        \u003Cb>输液反应：\u003C/b>曲妥珠单抗、帕妥珠单抗首次用药时要注意寒战、发热、呼吸异常等反应，出现时立即停药并对症处理。\n      \u003C/li>\n      \u003Cli>\n        \u003Cb>肝肾功能损伤：\u003C/b>多西他赛、卡铂有一定比例患者出现。化验肝肾功能显著异常时，减少或暂停相关药物使用。\n      \u003C/li>\n      \u003Cli>\n        \u003Cb>外周神经毒性：\u003C/b>多西他赛引起手足麻木，应注意手指、脚趾麻木或刺痛症状，如果影响日常生活，需要就诊调整用药。\n      \u003C/li>\n      \u003Cli>\n        \u003Cb>心脏毒性：\u003C/b>曲妥珠单抗、帕妥珠单抗可引起心功能减退，治疗期间定期行心脏超声。\n      \u003C/li>\n    \u003C/ul>\n    \u003Cdiv class=\"material-tip material-warning\">\u003Cspan class=\"material-emoji\">🚨\u003C/span>特别提醒：任何严重不适应立即报告医护人员，避免耽误最佳处理时机。\u003C/div>\n  \u003C/section>\n\n  \u003Csection class=\"material-section\">\n    \u003Ch2 class=\"material-section-title material-bg2\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">6. 特殊人群与个体化用药调整\u003C/h2>\n    \u003Cul class=\"material-list\">\n      \u003Cli>\n        \u003Cb>老年人：\u003C/b>根据肝、肾功能情况，下调多西他赛或卡铂剂量，曲妥珠单抗和帕妥珠单抗同理。\n      \u003C/li>\n      \u003Cli>\n        \u003Cb>肝肾功能损害者：\u003C/b>多西他赛代谢主要经肝，卡铂排泄主要靠肾，功能障碍需调整或暂停用药。\n      \u003C/li>\n      \u003Cli>\n        \u003Cb>生育要求：\u003C/b>化疗可能影响生殖能力，用药前建议充分咨询，必要时保存卵子。\n      \u003C/li>\n      \u003Cli>\n        \u003Cb>妊娠、哺乳期：\u003C/b>上述四药原则上禁用（或极为慎用），避免致畸或通过乳汁影响婴儿。\n      \u003C/li>\n    \u003C/ul>\n  \u003C/section>\n\n  \u003Csection class=\"material-section\">\n    \u003Ch2 class=\"material-section-title material-bg3\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">7. 储存条件与药品安全管理\u003C/h2>\n    \u003Cul class=\"material-list\">\n      \u003Cli>\n        \u003Cb>曲妥珠单抗：\u003C/b>2°C-8°C冷藏避光，勿冷冻。配液后如未使用24小时内需丢弃。\n      \u003C/li>\n      \u003Cli>\n        \u003Cb>帕妥珠单抗：\u003C/b>同样需冷藏密封，避免强光直射，药液变色或有沉淀禁止使用。\n      \u003C/li>\n      \u003Cli>\n        \u003Cb>多西他赛、卡铂：\u003C/b>储存环境2-8°C，原包装避光密闭保存，开瓶后剩余部分勿再次使用。\n      \u003C/li>\n      \u003Cli>\n        \u003Cb>废弃药品：\u003C/b>过期、剩余或用后药液应交由专业医疗废弃物处理，不可随意丢弃或冲入下水道。\n      \u003C/li>\n    \u003C/ul>\n    \u003Cdiv class=\"material-tip\">\u003Cspan class=\"material-emoji\">🧊\u003C/span>正确做法：全程冷链管理，避免室温暴露，药品在家中只允许短暂临时存放。\u003C/div>\n  \u003C/section>\n\n  \u003Csection class=\"material-section\">\n    \u003Ch2 class=\"material-section-title material-bg4\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">8. 漏服、过量与紧急处理\u003C/h2>\n    \u003Cul class=\"material-list\">\n      \u003Cli>\n        \u003Cb>漏用：\u003C/b>由于均为静脉注射药物，按化疗计划给药，如遇突发状况中断，及时就医评估后决定是否补充本周期用药。\n      \u003C/li>\n      \u003Cli>\n        \u003Cb>过量：\u003C/b>误用过量时，最常见为骨髓抑制和严重脏器损伤。此类情况务必即刻通知医务人员，严密观察生命体征，积极抢救。\n      \u003C/li>\n      \u003Cli>\n        \u003Cb>自行处理禁忌：\u003C/b>家庭中出现点滴相关不适等，应就地停止并尽快前往就诊，切忌采用自购药物缓解。\n      \u003C/li>\n    \u003C/ul>\n    \u003Cdiv class=\"material-tip\">\u003Cspan class=\"material-emoji\">🧑‍⚕️\u003C/span>实用建议：任何用药环节有疑问，第一时间咨询专业医疗人员。\u003C/div>\n  \u003C/section>\n\n  \u003Csection class=\"material-section\">\n    \u003Ch2 class=\"material-section-title material-bg1\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">9. 典型临床用药案例\u003C/h2>\n    \u003Cul class=\"material-list\">\n      \u003Cli>\n        一名37岁女性，使用TCbHP方案（曲妥珠单抗、帕妥珠单抗、多西他赛、卡铂）后出现严重骨髓抑制，及时对症处理后好转，再次化疗时严格监测血象。\n      \u003C/li>\n      \u003Cli>\n        临床上，合用二种HER2靶向药后心功能下降，因此每周期前均监测心脏状态，确保安全。\u003C/li>\n    \u003C/ul>\n  \u003C/section>\n\n  \u003Csection class=\"material-section\">\n    \u003Ch2 class=\"material-section-title material-bg2\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">10. 用药安全总结与重点提醒\u003C/h2>\n    \u003Cdiv class=\"material-summary\">\n      \u003Cspan class=\"material-emoji\">📌\u003C/span>\n      \u003Cspan>曲妥珠单抗、帕妥珠单抗、多西他赛、卡铂各有用法和风险。每一位用药者都需牢记：\u003Cbr>\n      （1）不随意更改剂量和用药计划；\u003Cbr>\n      （2）定期检查心脏及血常规等指标；\u003Cbr>\n      （3）遇到异常不适第一时间寻求医疗帮助。\u003Cbr>\n      这4类药需要严格按照化疗方案执行和全程医疗团队监管，才能最大化疗效、降低并发症。合理用药，就是守护健康的要塞。\u003C/span>\n    \u003C/div>\n  \u003C/section>\n\n  \u003Csection class=\"material-section material-reference-section\">\n    \u003Ch2 class=\"material-section-title material-bg-ref\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">参考文献\u003C/h2>\n    \u003Cul class=\"material-ref-list\">\n      \u003Cli>Slamon DJ, Leyland-Jones B, Shak S, et al. (2001). Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. \u003Ci>N Engl J Med\u003C/i>, 344(11), 783-792. \u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/11248153/\" target=\"_blank\">PubMed\u003C/a>\u003C/li>\n      \u003Cli>Baselga J, Cortés J, Kim SB, et al. (2012). Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. \u003Ci>N Engl J Med\u003C/i>, 366(2), 109-119. \u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/22149875/\" target=\"_blank\">PubMed\u003C/a>\u003C/li>\n      \u003Cli>Fumoleau P, Trigo JM, Isambert N, et al. (1995). Docetaxel (Taxotere): an active drug for the treatment of advanced breast cancer. \u003Ci>J Clin Oncol\u003C/i>, 13(1), 124-131. \u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/7799010/\" target=\"_blank\">PubMed\u003C/a>\u003C/li>\n      \u003Cli>Calvert AH, Newell DR, Gumbrell LA, et al. (1989). Carboplatin dosage: prospective evaluation of a simple formula based on renal function. \u003Ci>J Clin Oncol\u003C/i>, 7(11), 1748-1756. \u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/2681557/\" target=\"_blank\">PubMed\u003C/a>\u003C/li>\n    \u003C/ul>\n  \u003C/section>\n\u003C/div>\n\n\u003Cstyle>\n.material-guide-container {\n  max-width: 860px;\n  margin: 40px auto 80px auto;\n  padding: 36px 28px 36px 28px;\n  box-sizing: border-box;\n  background: #f5f7fa;\n  border-radius: 20px;\n  box-shadow: 0 4px 34px rgba(154,175,198,0.17), 0 1.5px 4.5px rgba(196,196,196,0.05);\n}\n\n.material-title {\n  font-size: 2.3em;\n  font-weight: 700;\n  text-align: center;\n  margin-bottom: 34px;\n  min-height: 60px;\n  line-height: 1.3;\n  background: -webkit-linear-gradient(left,#3a6ea5,#b5aedc 65%);\n  -webkit-background-clip: text;\n  -webkit-text-fill-color: transparent;\n  background-clip: text;\n}\n\n.material-lead {\n  display: flex;\n  align-items: flex-start;\n  margin-bottom: 30px;\n  background: #e3eaf5;\n  border-radius: 12px;\n  padding: 20px 23px;\n  font-size: 1.17em;\n  font-weight: 400;\n  color: #42608d;\n}\n.material-lead .material-emoji {\n  font-size: 2em;\n  margin-right: 15px;\n  margin-top: 4px;\n}\n.material-lead-text {\n  flex: 1;\n}\n\n.material-section {\n  margin-bottom: 24px;\n}\n.material-section-title {\n  font-size: 1.38em;\n  padding: 21px 16px 21px 44px;\n  border-radius: 12px 12px 0 0;\n  font-weight: 600;\n  margin-bottom: 18px;\n  background-repeat: no-repeat;\n  background-size: cover;\n  line-height: 1.4;\n  color: #283753;\n  letter-spacing: 0.02em;\n  position: relative;\n  z-index: 1;\n}\n.material-bg1 {\n  background: linear-gradient(90deg, #eff6fe 75%, #f7f3fd 100%);\n}\n.material-bg2 {\n  background: linear-gradient(90deg, #f7f3fd 60%, #f2f5fa 100%);\n}\n.material-bg3 {\n  background: linear-gradient(90deg, #ecf5fa 75%, #f8f4fa 100%);\n}\n.material-bg4 {\n  background: linear-gradient(90deg, #f5f7fa 65%, #eaf3fc 100%);\n}\n.material-bg-ref {\n  background: linear-gradient(90deg,#f8f8fb 80%,#ecebfe 100%);\n}\n\n.material-list {\n  margin: 0 0 8px 0;\n  padding: 0 0 0 30px;\n  font-size: 1.08em;\n  color: #344054;\n  letter-spacing: 0.01em;\n}\n.material-list li {\n  margin-bottom: 13px;\n  line-height: 1.89;\n}\n\n.material-tip {\n  margin: 21px 8px 0 8px;\n  padding: 11px 19px 11px 19px;\n  border-left: 4px solid #b0cbf9;\n  background: #f3f6ff;\n  border-radius: 6px;\n  font-size: 1em;\n  color: #395775;\n  display: flex;\n  align-items: center;\n  gap: 7px;\n  font-weight: 500;\n  max-width: 94%;\n}\n.material-tip .material-emoji {\n  font-size: 1.25em;\n}\n.material-warning {\n  border-left-color: #fa9a85;\n  background: #fff5f2;\n  color: #9a2f19;\n}\n\n.material-summary {\n  padding: 17px 22px;\n  margin: 15px 12px 0 12px;\n  background: #f6faff;\n  border-radius: 9px;\n  font-size: 1.12em;\n  color: #213465;\n  font-weight: 500;\n  display: flex;\n  align-items: flex-start;\n  gap: 11px;\n  line-height: 1.8;\n}\n.material-summary .material-emoji {\n  font-size: 2em;\n}\n\n.material-reference-section {\n  margin-top: 35px;\n  margin-bottom: 10px;\n  font-size: 1em;\n  color: #4d5b74;\n}\n.material-section-title.material-bg-ref {\n  color: #8A7DCF;\n}\n.material-ref-list {\n  margin: 0 0 0 28px;\n  padding: 0;\n}\n.material-ref-list li {\n  margin-bottom: 12px;\n  line-height: 1.7;\n  word-break: break-all;\n}\n.material-ref-list a {\n  color: #3a68a5;\n  text-decoration: underline;\n  font-size: 0.95em;\n  margin-left: 6px;\n}\n\u003C/style>\n","\u003Cdiv class=\"material-guide-container\">\n  \u003Ch2 id=\"material_title\" class=\"material-title\" style=\"color",550,"2025-08-14 10:54:12","TCbHP化疗方案, 曲妥珠单抗, 帕妥珠单抗, 多西他赛, 卡铂, 用药安全, 化疗药物, 药物管理","本指南详细介绍TCbHP化疗方案的四种药物使用要点，涵盖药理机制、剂型特性、合理用法、风险管理和特殊人群调整，帮助患者安全有效用药。","2025-08-21 13:18:00",2,[34],{"menuId":35,"menuName":36,"parentId":21,"orderNum":32,"path":37,"component":38,"isFrame":39,"isCache":40,"menuType":41,"visible":42,"status":21,"createDept":6,"remark":23,"createTime":43,"children":44,"columnImage":45,"columnLogo":46,"uncheckedLogo":6,"checkedLogo":6,"isHot":42,"isHome":21,"forceLogin":21,"color":47,"seoTitle":48,"seoKeywords":49,"seoDescription":50,"contentNum":6,"promotionalPoster":51,"menuFrame":7,"innerLink":7,"parentView":7,"routeName":52,"routerPath":37,"componentInfo":38},"1986713082609147906","健康科普","article","/article.html","1","0","T",1,"2025-11-07 16:31:25",[],"https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:49/d4291d16-ed1c-48dd-84c8-ec1f85980b75.png","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:52/6fe64094-9416-442c-a66d-032fb292666a.png","#c8e6ca","健康科普助力健康中国2030:共享健康知识新理念","健康科普, 健康中国, 科普知识, 健康家庭, 性健康, 营养健康, 运动健康, 科普宣传","探索健康科普在健康中国行动中的重要角色,了解最新的健康科普创新大赛、动漫及短视频,传播健康知识,助力全民健康。","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:56/bd33f471-6c54-4d1b-a364-b06973dbc144.png","Article","癌症肿瘤,重大疾病",true,{"code":9,"msg":10,"message":6,"data":56,"success":54},{"pageNo":42,"pageSize":57,"result":58,"totalSize":21},10,[],{"code":9,"msg":10,"message":6,"data":60,"success":54},{"authors":61,"appraiseDimensionScoresVos":62},[],[]]